Master bibliography — hypertensive heart disease¶

Last curated: 2026-08-31. One line per paper, with the wiki pages that cite it. All 243 PMIDs from the 2026-08-29 build were obtained or re-resolved through live PubMed E-utilities queries in that session; the 15 entries added by the 2026-08-31 sweep were each resolved live in that sweep, bringing the total to 258. Group placement follows the first substantive domain in which a source is used; cross-domain use is shown in “cited by.”

Companion evidence registers: guidelines/REGISTRY.md, statistics/STATISTICS.md, patient-voice/README.md, and notes/.

Foundations, definitions, epidemiology and attribution¶

Dahlöf B, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. PMID 11937178 — tags: [overview] — cited by: blood-pressure-targets.md, outcomes-and-risk-stratification.md, overview.md, pharmacologic-prevention-and-regression.md
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. PMID 12479763 — tags: [overview] — cited by: overview.md, pharmacologic-prevention-and-regression.md
Devereux RB, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-62. PMID 15326072 — tags: [overview] — cited by: blood-pressure-targets.md, clinical-trials-landscape.md, overview.md, pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Okin PM, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9. PMID 15547161 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, outcomes-and-risk-stratification.md, overview.md, pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Devereux RB, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-6. PMID 15547162 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, outcomes-and-risk-stratification.md, overview.md, pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Prisant LM. Hypertensive heart disease. J Clin Hypertens (Greenwich). 2005;7:231-8. PMID 15860963 — tags: [nosology-and-attribution] — cited by: nosology-and-attribution.md
Diamond JA, et al. Hypertensive heart disease. Hypertens Res. 2005;28:191-202. PMID 16097361 — tags: [nosology-and-attribution] — cited by: nosology-and-attribution.md
Bhatt DL, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-401. PMID 24678939 — tags: [overview] — cited by: clinical-trials-landscape.md, overview.md, pharmacologic-prevention-and-regression.md, red-flags-and-safety-concerns.md
Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6. PMID 24804791 — tags: [nosology-and-attribution] — cited by: nosology-and-attribution.md, outcomes-and-risk-stratification.md, secondary-hypertension-and-modifiers.md, ventricular-remodeling.md
Williams B, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-2068. PMID 26414968 — tags: [overview] — cited by: overview.md, pharmacologic-prevention-and-regression.md
SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-16. PMID 26551272 — tags: [overview] — cited by: blood-pressure-targets.md, overview.md, red-flags-and-safety-concerns.md
Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967. PMID 26724178 — tags: [overview] — cited by: blood-pressure-targets.md, overview.md, pharmacologic-prevention-and-regression.md
Monticone S, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41-50. PMID 29129575 — tags: [overview] — cited by: guidelines.md, overview.md, pharmacologic-prevention-and-regression.md, secondary-hypertension-and-modifiers.md
Hinderliter AL, et al. Implementing ABPM into Clinical Practice. Curr Hypertens Rep. 2018;20:5. PMID 29404785 — tags: [overview] — cited by: blood-pressure-targets.md, overview.md
Villela PB, et al. Cerebrovascular and hypertensive diseases as multiple causes of death in Brazil from 2004 to 2013. Public Health. 2018;161:36-42. PMID 29870833 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Bierrenbach AL, et al. Redistribution of heart failure deaths using two methods: linkage of hospital records with death certificate data and multiple causes of death data. Cad Saude Publica. 2019;35:e00135617. PMID 31166417 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Wu X, et al. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e15985. PMID 31261504 — tags: [overview] — cited by: overview.md, secondary-hypertension-and-modifiers.md
Nwabuo CC, et al. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22:11. PMID 32016791 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, diastolic-dysfunction-and-hfpef.md, epidemiology-and-burden.md, nosology-and-attribution.md, outcomes-and-risk-stratification.md, overview.md, patient-experience-and-advocacy.md, ventricular-remodeling.md
Persell SD, et al. Effect of Home Blood Pressure Monitoring via a Smartphone Hypertension Coaching Application or Tracking Application on Adults With Uncontrolled Hypertension: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e200255. PMID 32119093 — tags: [overview] — cited by: blood-pressure-targets.md, overview.md, patient-experience-and-advocacy.md
Mouton AJ, et al. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res. 2020;126:789-806. PMID 32163341 — tags: [overview] — cited by: lifestyle-and-population-prevention.md, overview.md, secondary-hypertension-and-modifiers.md
Tadic M, et al. Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus. Heart Fail Rev. 2021;26:1383-1390. PMID 32170529 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, guidelines.md, overview.md
Filippou CD, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2020;11:1150-1160. PMID 32330233 — tags: [overview] — cited by: lifestyle-and-population-prevention.md, overview.md
Yi S, et al. Prediction of stroke with electrocardiographic left ventricular hypertrophy in hypertensive patients: A meta-analysis. J Electrocardiol. 2020;61:27-31. PMID 32504899 — tags: [overview] — cited by: outcomes-and-risk-stratification.md, overview.md
Padmanabhan S, et al. Genomics of hypertension: the road to precision medicine. Nat Rev Cardiol. 2021;18:235-250. PMID 33219353 — tags: [overview] — cited by: overview.md
Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625-1636. PMID 33933205 — tags: [overview] — cited by: blood-pressure-targets.md, outcomes-and-risk-stratification.md, overview.md
SPRINT Research Group. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021;384:1921-1930. PMID 34010531 — tags: [overview] — cited by: blood-pressure-targets.md, clinical-trials-landscape.md, overview.md, red-flags-and-safety-concerns.md
Miazgowski T, et al. Epidemiology of hypertensive heart disease in Poland: findings from the Global Burden of Disease Study 2016. Arch Med Sci. 2021;17:874-880. PMID 34336015 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957-980. PMID 34450083 — tags: [overview] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md, overview.md
Zhang W, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385:1268-1279. PMID 34491661 — tags: [overview] — cited by: blood-pressure-targets.md, clinical-trials-landscape.md, overview.md
Yan T, et al. Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study. J Am Heart Assoc. 2023;12:e027852. PMID 36892088 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Nemtsova V, et al. Hypertensive Heart Disease: A Narrative Review Series-Part 1: Pathophysiology and Microstructural Changes. J Clin Med. 2023;12. PMID 37048689 — tags: [overview] — cited by: diagnosis-and-phenotyping.md, nosology-and-attribution.md, overview.md, ventricular-remodeling.md
Ismail TF, et al. Hypertensive Heart Disease-The Imaging Perspective. J Clin Med. 2023;12. PMID 37176563 — tags: [nosology-and-attribution] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, epidemiology-and-burden.md, guidelines.md, nosology-and-attribution.md
Deng Y, et al. Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial. Hypertension. 2023;80:1834-1842. PMID 37259845 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, blood-pressure-targets.md, clinical-trials-landscape.md, outcomes-and-risk-stratification.md, overview.md
Masenga SK, et al. Hypertensive heart disease: risk factors, complications and mechanisms. Front Cardiovasc Med. 2023;10:1205475. PMID 37342440 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Chan II. Interpreting the observed sex differences in hypertensive heart disease burden. Eur J Prev Cardiol. 2024;31:21-22. PMID 37607268 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Yang R, et al. Global, regional, and national burden of hypertensive heart disease among older adults in 204 countries and territories between 1990 and 2019: a trend analysis. Chin Med J (Engl). 2023;136:2421-2430. PMID 37698022 — tags: [overview] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md, overview.md
González A, et al. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management. Hypertension. 2024;81:218-228. PMID 38084597 — tags: [nosology-and-attribution] — cited by: biomarkers-and-imaging-markers.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md, nosology-and-attribution.md, outcomes-and-risk-stratification.md, ventricular-remodeling.md
GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100-2132. PMID 38582094 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Abughazaleh S, et al. Trends of hypertensive heart disease prevalence and mortality in the United States between the period 1990-2019, Global burden of disease database. Curr Probl Cardiol. 2024;49:102621. PMID 38718934 — tags: [overview] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md, overview.md
Đorđević DB, et al. Hypertension and left ventricular hypertrophy. J Hypertens. 2024;42:1505-1515. PMID 38747417 — tags: [overview] — cited by: overview.md
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162-2203. PMID 38762324 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md, lifestyle-and-population-prevention.md
Gallo G, et al. Hypertension and Heart Failure: From Pathophysiology to Treatment. Int J Mol Sci. 2024;25. PMID 38928371 — tags: [overview] — cited by: diastolic-dysfunction-and-hfpef.md, heart-failure-management.md, nosology-and-attribution.md, overview.md
Huang X, et al. Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment. Rev Cardiovasc Med. 2024;25:93. PMID 39076964 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Zhao Q, et al. Cardiac magnetic resonance imaging for discrimination of hypertensive heart disease and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1421013. PMID 39156132 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, overview.md, red-flags-and-safety-concerns.md
McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. PMID 39210715 — tags: [overview] — cited by: blood-pressure-targets.md, diagnosis-and-phenotyping.md, guidelines.md, overview.md, pharmacologic-prevention-and-regression.md, red-flags-and-safety-concerns.md
Vukadinović D, et al. Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis. Circulation. 2024;150:1599-1611. PMID 39355923 — tags: [overview] — cited by: arrhythmia-and-atrial-remodeling.md, clinical-trials-landscape.md, overview.md, patient-experience-and-advocacy.md, pharmacologic-prevention-and-regression.md, red-flags-and-safety-concerns.md
Chen QF, et al. Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021. Eur Heart J Qual Care Clin Outcomes. 2025;11:493-509. PMID 39774847 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Ran J, et al. Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: results from the global burden of disease study 2021. Biomark Res. 2025;13:16. PMID 39849627 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Wang BX. Diagnosis and Management of Hypertensive Heart Disease: Incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline Updates. J Cardiovasc Dev Dis. 2025;12. PMID 39997480 — tags: [nosology-and-attribution] — cited by: guidelines.md, nosology-and-attribution.md
Goyal A, et al. Temporal trends and disparities in mortality from hypertensive heart disease with heart failure: A nationwide analysis (1999-2020). Int J Cardiol Cardiovasc Risk Prev. 2025;24:200378. PMID 40083536 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Global Cardiovascular Risk Consortium, et al. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. N Engl J Med. 2025;393:125-138. PMID 40162648 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Khalid N, et al. The Global Disease Burden of Hypertensive Heart Disease from 1990 to 2019: A Gender-Stratified Joinpoint Analysis. J Clin Med. 2025;14. PMID 40565965 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Liu F, et al. Trends analysis of the global burden of hypertensive heart disease from 1990 to 2021: a population-based study. BMC Public Health. 2025;25:2233. PMID 40604684 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Lee V, et al. Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial. Nat Commun. 2025;16:6981. PMID 40739095 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, clinical-trials-landscape.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md, overview.md, pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Bellicini MG. Hypertensive heart disease: is it really a pathology? Hypertens Res. 2025;48:2737-2739. PMID 40760163 — tags: [nosology-and-attribution] — cited by: nosology-and-attribution.md
Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86:1567-1678. PMID 40815242 — tags: [overview] — cited by: blood-pressure-targets.md, diagnosis-and-phenotyping.md, guidelines.md, overview.md, pharmacologic-prevention-and-regression.md, red-flags-and-safety-concerns.md
Sun Z, et al. Global burden of hypertensive heart disease attributable to high body mass index from 1990 to 2021: a multidimensional analysis and public health response. Front Cardiovasc Med. 2025;12:1570390. PMID 40873620 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
Hwang IC, et al. Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. J Am Heart Assoc. 2025;14:e042032. PMID 40970541 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, clinical-trials-landscape.md, diagnosis-and-phenotyping.md, outcomes-and-risk-stratification.md, overview.md, ventricular-remodeling.md
Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J Am Coll Cardiol. 2025;86:2167-2243. PMID 40990886 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Xu Z, et al. Hypertensive heart disease mortality trends attributable to high body mass index over the period 1990-2021 and projections up to 2040. Arch Med Sci. 2025;21:1164-1176. PMID 41078923 — tags: [epidemiology-and-burden] — cited by: epidemiology-and-burden.md
GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:1811-1872. PMID 41092928 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Li S, et al. Systematic analysis of global ischemic heart disease and hypertensive heart disease burden, 1990-2021: projections to 2050. BMC Public Health. 2025;26:122. PMID 41350658 — tags: [nosology-and-attribution] — cited by: epidemiology-and-burden.md, nosology-and-attribution.md
Sharp A, et al. Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study. Eur J Heart Fail. 2026. PMID 41771092 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, clinical-trials-landscape.md, diagnosis-and-phenotyping.md, guidelines.md, heart-failure-management.md, outcomes-and-risk-stratification.md, overview.md, patient-experience-and-advocacy.md
Lertsiripatarajit P, et al. Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease. Clin Hypertens. 2026;32:e14. PMID 41953289 — tags: [overview] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, outcomes-and-risk-stratification.md, overview.md
Awashra A, et al. Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications. Catheter Cardiovasc Interv. 2026;108:357-375. PMID 42144689 — tags: [overview] — cited by: overview.md
Sliwa K, et al. Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study. Lancet. 2026;:S0140-6736(26)01657-0. PMID 42669305 — tags: [epidemiology-and-burden, heart-failure-management, landmark] — cited by: epidemiology-and-burden.md, heart-failure-management.md, notes/sliwa-2026-thesus-hf2.md

Diagnosis, phenotyping, imaging and biomarkers¶

de Simone G, et al. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension. 2002;40:470-6. PMID 12364349 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, outcomes-and-risk-stratification.md, ventricular-remodeling.md
Weber KT. Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens. 2004;22:47-50. PMID 15106793 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, ventricular-remodeling.md
Cuspidi C, et al. Hypertensive myocardial fibrosis. Nephrol Dial Transplant. 2006;21:20-3. PMID 16263734 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, ventricular-remodeling.md
Alfakih K, et al. The assessment of left ventricular hypertrophy in hypertension. J Hypertens. 2006;24:1223-30. PMID 16794466 — tags: [diagnosis-and-phenotyping] — cited by: diagnosis-and-phenotyping.md
Pewsner D, et al. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711. PMID 17726091 — tags: [diagnosis-and-phenotyping] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, outcomes-and-risk-stratification.md, red-flags-and-safety-concerns.md
Asayama K, et al. Out-of-office blood pressure improves risk stratification in normotension and prehypertension people. Curr Hypertens Rep. 2014;16:478. PMID 25139777 — tags: [diagnosis-and-phenotyping] — cited by: diagnosis-and-phenotyping.md
Saito M, et al. Prognostic Implications of LV Strain Risk Score in Asymptomatic Patients With Hypertensive Heart Disease. JACC Cardiovasc Imaging. 2016;9:911-21. PMID 27344417 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, outcomes-and-risk-stratification.md
Obokata M, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136:6-19. PMID 28381470 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md, secondary-hypertension-and-modifiers.md
Mavrogeni S, et al. The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease. BMC Cardiovasc Disord. 2017;17:132. PMID 28535761 — tags: [diagnosis-and-phenotyping] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md
Tucker KL, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389. PMID 28926573 — tags: [diagnosis-and-phenotyping] — cited by: blood-pressure-targets.md, diagnosis-and-phenotyping.md, lifestyle-and-population-prevention.md, patient-experience-and-advocacy.md, pharmacologic-prevention-and-regression.md
Reddy YNV, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138:861-870. PMID 29792299 — tags: [diagnosis-and-phenotyping] — cited by: diagnosis-and-phenotyping.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Stewart MH, et al. Prognostic Implications of Left Ventricular Hypertrophy. Prog Cardiovasc Dis. 2018;61:446-455. PMID 30408469 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, outcomes-and-risk-stratification.md, ventricular-remodeling.md
Zhang W, et al. Consistency of left ventricular hypertrophy diagnosed by electrocardiography and echocardiography: the Northern Shanghai Study. Clin Interv Aging. 2019;14:549-556. PMID 30880935 — tags: [diagnosis-and-phenotyping] — cited by: diagnosis-and-phenotyping.md
Yang WY, et al. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA. 2019;322:409-420. PMID 31386134 — tags: [diagnosis-and-phenotyping] — cited by: blood-pressure-targets.md, diagnosis-and-phenotyping.md
Neisius U, et al. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS One. 2019;14:e0221061. PMID 31433823 — tags: [diagnosis-and-phenotyping] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md
Pieske B, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297-3317. PMID 31504452 — tags: [diagnosis-and-phenotyping] — cited by: diagnosis-and-phenotyping.md, diastolic-dysfunction-and-hfpef.md
Bressman M, et al. Determination of Sensitivity and Specificity of Electrocardiography for Left Ventricular Hypertrophy in a Large, Diverse Patient Population. Am J Med. 2020;133:e495-e500. PMID 32194027 — tags: [diagnosis-and-phenotyping] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md, outcomes-and-risk-stratification.md
Huang QF, et al. Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension. Hypertension. 2021;77:254-264. PMID 33390042 — tags: [diagnosis-and-phenotyping] — cited by: blood-pressure-targets.md, diagnosis-and-phenotyping.md
McManus RJ, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021;372:m4858. PMID 33468518 — tags: [diagnosis-and-phenotyping] — cited by: diagnosis-and-phenotyping.md, lifestyle-and-population-prevention.md, patient-experience-and-advocacy.md
Giusca S, et al. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23:92. PMID 34247623 — tags: [diagnosis-and-phenotyping] — cited by: biomarkers-and-imaging-markers.md, diagnosis-and-phenotyping.md
Tadic M, et al. Effect of long-term antihypertensive therapy on myocardial strain: a meta-analysis. J Hypertens. 2022;40:641-647. PMID 35102087 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, ventricular-remodeling.md
Redfield MM, et al. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329:827-838. PMID 36917048 — tags: [biomarkers-and-imaging-markers] — cited by: biomarkers-and-imaging-markers.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Zhang DY, et al. Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis. Eur Heart J. 2025;46:2974-2987. PMID 40249369 — tags: [diagnosis-and-phenotyping] — cited by: blood-pressure-targets.md, diagnosis-and-phenotyping.md
Croon PM, et al. Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy. JAMA. 2026;:e2616785. PMID 42663420 — tags: [diagnosis-and-phenotyping, differential-diagnosis, machine-learning] — cited by: diagnosis-and-phenotyping.md
Docherty KF, et al. Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study. Eur Heart J. 2026;:ehag686. PMID 42663089 — tags: [biomarkers-and-imaging-markers, natriuretic-peptides, thresholds] — cited by: biomarkers-and-imaging-markers.md

Ventricular, diastolic and atrial remodeling¶

Messerli FH. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. Am J Hypertens. 1993;6:335-6. PMID 7685177 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Dunn FG, et al. Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens. 1993;11:1003-10. PMID 8258663 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Schmieder RE, et al. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-13. PMID 8622227 — tags: [ventricular-remodeling] — cited by: pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Wachtell K, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9. PMID 15734615 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, pharmacologic-prevention-and-regression.md
Melenovsky V, et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198-207. PMID 17222731 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Sowers JR. Hypertension myocardial fibrosis. J Clin Hypertens (Greenwich). 2007;9:558-9. PMID 17617768 — tags: [ventricular-remodeling] — cited by: ventricular-remodeling.md
Okin PM, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med. 2007;147:311-9. PMID 17785486 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Wachtell K, et al. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. Ther Adv Cardiovasc Dis. 2008;2:507-13. PMID 19124445 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Lip GY, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72. PMID 19762550 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Fagard RH, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-91. PMID 19770405 — tags: [ventricular-remodeling] — cited by: pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100. PMID 20299623 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Pierdomenico SD, et al. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens. 2010;23:876-81. PMID 20414193 — tags: [ventricular-remodeling] — cited by: outcomes-and-risk-stratification.md, pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Wachtell K, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010;19:169-75. PMID 20438307 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Larstorp AC, et al. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension. 2012;60:347-53. PMID 22753219 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Paulus WJ, et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-71. PMID 23684677 — tags: [ventricular-remodeling] — cited by: diastolic-dysfunction-and-hfpef.md, ventricular-remodeling.md
Shah AM. Ventricular remodeling in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:341-9. PMID 24097113 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md, outcomes-and-risk-stratification.md
Chrispin J, et al. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:2007-13. PMID 24657688 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-92. PMID 24716680 — tags: [diastolic-dysfunction-and-hfpef] — cited by: clinical-trials-landscape.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md, red-flags-and-safety-concerns.md
Woodiwiss AJ, et al. Obesity and left ventricular hypertrophy: the hypertension connection. Curr Hypertens Rep. 2015;17:539. PMID 25794954 — tags: [ventricular-remodeling] — cited by: lifestyle-and-population-prevention.md, secondary-hypertension-and-modifiers.md, ventricular-remodeling.md
Shenasa M, et al. Left ventricular hypertrophy and arrhythmogenesis. Card Electrophysiol Clin. 2015;7:207-20. PMID 26002387 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Shah SJ, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134:73-90. PMID 27358439 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Shenasa M, et al. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol. 2017;237:60-63. PMID 28285801 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, outcomes-and-risk-stratification.md
Tsioufis C, et al. Biomarkers of Atrial Fibrillation in Hypertension. Curr Med Chem. 2019;26:888-897. PMID 28990508 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Schmieder RE, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38:3308-3317. PMID 29029087 — tags: [ventricular-remodeling] — cited by: clinical-trials-landscape.md, pharmacologic-prevention-and-regression.md, ventricular-remodeling.md
Beltrami M, et al. The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction. Int J Clin Pract. 2018;72. PMID 29283475 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md
Cangemi R, et al. Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. Am J Cardiol. 2019;124:723-728. PMID 31266594 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Solomon SD, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381:1609-1620. PMID 31475794 — tags: [diastolic-dysfunction-and-hfpef] — cited by: clinical-trials-landscape.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Yildiz M, et al. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020;63:10-21. PMID 31759953 — tags: [ventricular-remodeling] — cited by: ventricular-remodeling.md
Cohen JB, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020;8:172-184. PMID 31926856 — tags: [diastolic-dysfunction-and-hfpef] — cited by: clinical-trials-landscape.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Steinberg JS, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323:248-255. PMID 31961420 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, clinical-trials-landscape.md
Camici PG, et al. Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res. 2020;116:806-816. PMID 31999329 — tags: [ventricular-remodeling] — cited by: diastolic-dysfunction-and-hfpef.md, ventricular-remodeling.md
Nadarajah R, et al. Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans? J Hum Hypertens. 2021;35:492-498. PMID 33674703 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, outcomes-and-risk-stratification.md
Vasan RS, et al. Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community. Curr Cardiol Rep. 2021;23:86. PMID 34081212 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, outcomes-and-risk-stratification.md
Eichenlaub M, et al. Left Atrial Hypertension, Electrical Conduction Slowing, and Mechanical Dysfunction - The Pathophysiological Triad in Atrial Fibrillation-Associated Atrial Cardiomyopathy. Front Physiol. 2021;12:670527. PMID 34421634 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451-1461. PMID 34449189 — tags: [diastolic-dysfunction-and-hfpef] — cited by: clinical-trials-landscape.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Cauwenberghs N, et al. Subclinical heart remodeling and dysfunction in relation to peripheral endothelial dysfunction: A general population study. Microcirculation. 2021;28:e12731. PMID 34569675 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md
Walker M, et al. Atrial Fibrillation and Hypertension: "Quo Vadis". Curr Hypertens Rev. 2022;18:39-53. PMID 35023459 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Nawar K, et al. Renal denervation for atrial fibrillation: a comprehensive updated systematic review and meta-analysis. J Hum Hypertens. 2022;36:887-897. PMID 35094013 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, clinical-trials-landscape.md
Zhou D, et al. Prevalence and prognosis of left ventricular diastolic dysfunction in community hypertension patients. BMC Cardiovasc Disord. 2022;22:265. PMID 35698035 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md, outcomes-and-risk-stratification.md
Heradien M, et al. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial. Heart Rhythm. 2022;19:1765-1773. PMID 35781044 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, clinical-trials-landscape.md
Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387:1089-1098. PMID 36027570 — tags: [diastolic-dysfunction-and-hfpef] — cited by: clinical-trials-landscape.md, diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Vaduganathan M, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-767. PMID 36041474 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Aune D, et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023;38:145-178. PMID 36626102 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md, outcomes-and-risk-stratification.md
Anker SD, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023;25:936-955. PMID 37461163 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md, heart-failure-management.md
Lee V, et al. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. Front Cardiovasc Med. 2023;10:1248468. PMID 37674806 — tags: [ventricular-remodeling] — cited by: clinical-trials-landscape.md, ventricular-remodeling.md
Bejarano-Arosemena R, et al. Interatrial Block, Bayés Syndrome, Left Atrial Enlargement, and Atrial Failure. J Clin Med. 2023;12. PMID 38068382 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Shinohara K. Renal denervation for hypertensive heart disease and atrial fibrillation. Hypertens Res. 2024;47:2665-2670. PMID 38877310 — tags: [arrhythmia-and-atrial-remodeling] — cited by: arrhythmia-and-atrial-remodeling.md
Kim HL, et al. Arterial Stiffness and Heart Failure With Preserved Ejection Fraction. J Korean Med Sci. 2024;39:e195. PMID 38887204 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md
Durante A, et al. Systemic and Cardiac Microvascular Dysfunction in Hypertension. Int J Mol Sci. 2024;25. PMID 39769057 — tags: [ventricular-remodeling] — cited by: ventricular-remodeling.md
Peikert A, et al. Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment. Eur Heart J. 2026;47:37-53. PMID 40892534 — tags: [diastolic-dysfunction-and-hfpef] — cited by: diastolic-dysfunction-and-hfpef.md
Lu H, et al. Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials. Eur J Heart Fail. 2026;:xuag245. PMID 42669134 — tags: [diastolic-dysfunction-and-hfpef, blood-pressure-targets] — cited by: diastolic-dysfunction-and-hfpef.md
Shahmohamadi E, et al. Non-linear associations between blood pressure and clinical outcomes in atrial fibrillation: A systematic review and dose-response meta-analysis. Europace. 2026;:euag223. PMID 42663497 — tags: [arrhythmia-and-atrial-remodeling, blood-pressure-targets] — cited by: arrhythmia-and-atrial-remodeling.md

Risk, outcomes and secondary modifiers¶

Lauer MS. Left ventricular hypertrophy and cardiovascular prognosis. Cleve Clin J Med. 1995;62:169-75. PMID 7606829 — tags: [outcomes-and-risk-stratification] — cited by: outcomes-and-risk-stratification.md
Agarwal R. Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring. Curr Opin Nephrol Hypertens. 2006;15:309-13. PMID 16609300 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Toja PM, et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf). 2012;76:332-8. PMID 21854405 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Paoletti E. Left ventricular hypertrophy and progression of chronic kidney disease. J Nephrol. 2012;25:847-50. PMID 22460180 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Iida M, et al. Thyroid hormone within the normal range is associated with left ventricular mass in patients with hypertension. J Am Soc Hypertens. 2012;6:261-9. PMID 22664232 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Khatib R, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One. 2014;9:e84238. PMID 24454721 — tags: [secondary-hypertension-and-modifiers] — cited by: lifestyle-and-population-prevention.md, patient-experience-and-advocacy.md, pharmacologic-prevention-and-regression.md, secondary-hypertension-and-modifiers.md
Quail MA, et al. Abnormal Wave Reflections and Left Ventricular Hypertrophy Late After Coarctation of the Aorta Repair. Hypertension. 2017;69:501-509. PMID 28115510 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Agrawal S, et al. Pheochromocytoma and stress cardiomyopathy: Insight into pathogenesis. World J Cardiol. 2017;9:255-260. PMID 28400922 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Hundemer GL, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51-59. PMID 29129576 — tags: [secondary-hypertension-and-modifiers] — cited by: pharmacologic-prevention-and-regression.md, secondary-hypertension-and-modifiers.md
Cuspidi C, et al. Targeting Concentric Left Ventricular Hypertrophy in Obstructive Sleep Apnea Syndrome. A Meta-analysis of Echocardiographic Studies. Am J Hypertens. 2020;33:310-315. PMID 31863113 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Tsai CH, et al. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens. 2021;35:131-147. PMID 33067554 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Egbe AC, et al. Persistent Hypertension and Left Ventricular Hypertrophy After Repair of Native Coarctation of Aorta in Adults. Hypertension. 2021;78:672-680. PMID 34247510 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Reincke M, et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9:876-892. PMID 34798068 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Verdecchia P, et al. Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes. Hypertension. 2022;79:1028-1036. PMID 35166125 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Sarathy H, et al. Evaluation and Management of Secondary Hypertension. Med Clin North Am. 2022;106:269-283. PMID 35227430 — tags: [secondary-hypertension-and-modifiers] — cited by: pharmacologic-prevention-and-regression.md, secondary-hypertension-and-modifiers.md
Tadic M, et al. The impact of continuous positive airway pressure on cardiac mechanics: Findings from a meta-analysis of echocardiographic studies. J Clin Hypertens (Greenwich). 2022;24:795-803. PMID 35695237 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Kaesler N, et al. Mapping cardiac remodeling in chronic kidney disease. Sci Adv. 2023;9:eadj4846. PMID 38000021 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Hundemer GL, et al. Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. Circulation. 2024;149:124-134. PMID 38031887 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Dobre MA, et al. Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives. Curr Opin Nephrol Hypertens. 2024;33:203-211. PMID 38193308 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Morbach C, et al. Cardiovascular status in endogenous cortisol excess: the prospective CV-CORT-EX study. Eur J Endocrinol. 2024;191:604-613. PMID 39556766 — tags: [secondary-hypertension-and-modifiers] — cited by: secondary-hypertension-and-modifiers.md
Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2453-2495. PMID 40658480 — tags: [secondary-hypertension-and-modifiers] — cited by: guidelines.md, red-flags-and-safety-concerns.md, secondary-hypertension-and-modifiers.md

Blood-pressure targets and pharmacologic treatment¶

Beckett NS, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98. PMID 18378519 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, clinical-trials-landscape.md
ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. PMID 20228401 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, clinical-trials-landscape.md, red-flags-and-safety-concerns.md
SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15. PMID 23726159 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, red-flags-and-safety-concerns.md
Warwick J, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78. PMID 25880068 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md
Peralta CA, et al. Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial. Circulation. 2016;133:584-91. PMID 26762524 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, red-flags-and-safety-concerns.md
Wiysonge CS, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003. PMID 28107561 — tags: [pharmacologic-prevention-and-regression] — cited by: pharmacologic-prevention-and-regression.md
Fedorowski A, et al. Orthostatic hypotension and cardiovascular risk. Kardiol Pol. 2019;77:1020-1027. PMID 31713533 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, red-flags-and-safety-concerns.md
Thomopoulos C, et al. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020;38:1669-1681. PMID 32649628 — tags: [pharmacologic-prevention-and-regression] — cited by: pharmacologic-prevention-and-regression.md
Leache L, et al. Pharmacotherapy for hypertension-induced left ventricular hypertrophy. Cochrane Database Syst Rev. 2021;10:CD012039. PMID 34628642 — tags: [pharmacologic-prevention-and-regression] — cited by: pharmacologic-prevention-and-regression.md
Al-Makki A, et al. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2022;79:293-301. PMID 34775787 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, guidelines.md, pharmacologic-prevention-and-regression.md
Li X, et al. Intensive blood pressure control for patients aged over 60: A meta-analysis of the SPRINT, STEP, and ACCORD BP randomized controlled trials. Maturitas. 2023;172:52-59. PMID 37099984 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md, red-flags-and-safety-concerns.md
Zhou X, et al. Barriers and Facilitators of Medication Adherence in Hypertension Patients: A Meta-Integration of Qualitative Research. J Patient Exp. 2024;11:23743735241241176. PMID 38549805 — tags: [pharmacologic-prevention-and-regression] — cited by: patient-experience-and-advocacy.md, pharmacologic-prevention-and-regression.md
Guo X, et al. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet. 2025;406:1009-1019. PMID 40902616 — tags: [blood-pressure-targets] — cited by: blood-pressure-targets.md
Ji Y, et al. Achieved home systolic blood pressure and cardiovascular risk in older hypertensive patients. Hypertens Res. 2026;:10.1038/s41440-026-02787-2. PMID 42660976 — tags: [blood-pressure-targets, home-monitoring, STEP] — cited by: blood-pressure-targets.md
Antza C, et al. Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence. Br J Clin Pharmacol. 2026;:10.1002/bcp.70798. PMID 42663091 — tags: [secondary-hypertension-and-modifiers, obesity, pharmacotherapy] — cited by: catalogued only (narrative position paper; no wiki claim depends on it)

Heart failure, safety and clinical escalation¶

Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. PMID 10471456 — tags: [heart-failure-management] — cited by: heart-failure-management.md, red-flags-and-safety-concerns.md
McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. PMID 25176015 — tags: [heart-failure-management] — cited by: heart-failure-management.md
Watson K, et al. Focused Update on Pharmacologic Management of Hypertensive Emergencies. Curr Hypertens Rep. 2018;20:56. PMID 29884955 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008. PMID 31535829 — tags: [heart-failure-management] — cited by: heart-failure-management.md
Solomon SD, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141:352-361. PMID 31736342 — tags: [heart-failure-management] — cited by: heart-failure-management.md
Stavropoulos K, et al. Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. J Clin Hypertens (Greenwich). 2020;22:572-584. PMID 32049436 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Astarita A, et al. Hypertensive emergencies and urgencies in emergency departments: a systematic review and meta-analysis. J Hypertens. 2020;38:1203-1210. PMID 32510905 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-1424. PMID 32865377 — tags: [heart-failure-management] — cited by: heart-failure-management.md
Mathew R, et al. High-Dose Nitroglycerin Bolus for Sympathetic Crashing Acute Pulmonary Edema: A Prospective Observational Pilot Study. J Emerg Med. 2021;61:271-277. PMID 34215472 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. PMID 34447992 — tags: [heart-failure-management] — cited by: guidelines.md, heart-failure-management.md, red-flags-and-safety-concerns.md
Niklasson A, et al. Living with heart failure: patient experiences and implications for physical activity and daily living. ESC Heart Fail. 2022;9:1206-1215. PMID 35081667 — tags: [heart-failure-management] — cited by: heart-failure-management.md, patient-experience-and-advocacy.md
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. PMID 35363499 — tags: [heart-failure-management] — cited by: guidelines.md, heart-failure-management.md, red-flags-and-safety-concerns.md
Vaduganathan M, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023;44:2982-2993. PMID 37210743 — tags: [heart-failure-management] — cited by: heart-failure-management.md
Siddiqi TJ, et al. Clinical Outcomes in Hypertensive Emergency: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12:e029355. PMID 37421281 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-e156. PMID 38033089 — tags: [red-flags-and-safety-concerns] — cited by: guidelines.md, red-flags-and-safety-concerns.md
Wilson LM, et al. Management of Inpatient Elevated Blood Pressures : A Systematic Review of Clinical Practice Guidelines. Ann Intern Med. 2024;177:497-506. PMID 38560900 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Boulestreau R, et al. Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83:1688-1701. PMID 38658108 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
Miró Ò, et al. Hypertensive crisis in the elderly: epidemiological, clinical and outcome: EDEN-47 study. Gerontology. 2026;:1-21. PMID 42664163 — tags: [red-flags-and-safety-concerns, hypertensive-crisis, emergency] — cited by: red-flags-and-safety-concerns.md

Lifestyle, population prevention and lived experience¶

Neter JE, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878-84. PMID 12975389 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Cornelissen VA, et al. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004473. PMID 23525435 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
He FJ, et al. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346:f1325. PMID 23558162 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Chiavaroli L, et al. DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients. 2019;11. PMID 30764511 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Pesantes MA, et al. Disruption, changes, and adaptation: Experiences with chronic conditions in Mozambique, Nepal and Peru. Glob Public Health. 2020;15:372-383. PMID 31596656 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Mondesir FL, et al. Patient Perspectives on Factors Influencing Medication Adherence Among People with Coronary Heart Disease (CHD) and CHD Risk Factors. Patient Prefer Adherence. 2019;13:2017-2027. PMID 31819383 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Huang L, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020;368:m315. PMID 32094151 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Filippini T, et al. Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2020;9:e015719. PMID 32500831 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
de Castro QJT, et al. Physical Exercise Combined with Antihypertensive Drug Therapy on Left Ventricular Hypertrophy: Systematic Review and Meta-Analysis. High Blood Press Cardiovasc Prev. 2020;27:493-503. PMID 32776302 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Fu J, et al. Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension. J Am Heart Assoc. 2020;9:e016804. PMID 32975166 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Saco-Ledo G, et al. Exercise Reduces Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2020;9:e018487. PMID 33280503 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Filippini T, et al. Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies. Circulation. 2021;143:1542-1567. PMID 33586450 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Neal B, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385:1067-1077. PMID 34459569 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Dhungana RR, et al. Barriers, Enablers and Strategies for the Treatment and Control of Hypertension in Nepal: A Systematic Review. Front Cardiovasc Med. 2021;8:716080. PMID 34708082 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Li KC, et al. Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study. Circulation. 2022;145:1534-1541. PMID 35311346 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Shahin W, et al. A qualitative exploration of the impact of knowledge and perceptions about hypertension in medication adherence in Middle Eastern refugees and migrants. Explor Res Clin Soc Pharm. 2021;3:100038. PMID 35480607 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Sun Y, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022;399:1964-1975. PMID 35500594 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md, patient-experience-and-advocacy.md
Yin X, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart. 2022;108:1608-1615. PMID 35945000 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Galson SW, et al. Hypertension in an Emergency Department Population in Moshi, Tanzania; A Qualitative Study of Barriers to Hypertension Control. PLoS One. 2023;18:e0279377. PMID 36608026 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Kc D, et al. Illness Perception of Women Living with Hypertensive Condition: A Qualitative Study. J Nepal Health Res Counc. 2023;20:677-682. PMID 36974856 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Yuan Y, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat Med. 2023;29:973-981. PMID 37055566 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Yang S, et al. Effect of weight loss on blood pressure changes in overweight patients: A systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2023;25:404-415. PMID 37141231 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Edwards JJ, et al. Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. Br J Sports Med. 2023;57:1317-1326. PMID 37491419 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Lai X, et al. Cost-Effectiveness of Salt Substitute and Salt Supply Restriction in Eldercare Facilities: The DECIDE-Salt Cluster Randomized Clinical Trial. JAMA Netw Open. 2024;7:e2355564. PMID 38345818 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Ogugu EG, et al. Barriers to accessing care for cardiometabolic disorders in Malawi: partners as a source of resilience for people living with HIV. Int J Equity Health. 2024;23:83. PMID 38678232 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Kennedy C, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J. 2024;45:4124-4134. PMID 39217502 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md
Ghaderi Nasab Z, et al. Facilitators of medication adherence in patients with hypertension: a qualitative study. Front Public Health. 2024;12:1372698. PMID 39628801 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Endrias EE, et al. Exploring experiences and perspectives of patients on hypertension management in Southern Ethiopia: a phenomenological study. BMC Health Serv Res. 2024;24:1625. PMID 39702319 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md, patient-experience-and-advocacy.md
Frost J, et al. Understanding the self-management experiences of people with heart failure with preserved ejection fraction (HFpEF), their caregivers and the health care professionals who support them: Systematic review and qualitative meta-study. Br J Card Nurs. 2025;20:1-30. PMID 40625643 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Rubio R, et al. Quality of Life and Experience of Patients with Heart Failure with Preserved Ejection Fraction and Their Caregivers. J Clin Med. 2025;14. PMID 40649089 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Siedner MJ, et al. Home-Based Care for Hypertension in Rural South Africa. N Engl J Med. 2025;393:1304-1314. PMID 40888742 — tags: [lifestyle-and-population-prevention] — cited by: lifestyle-and-population-prevention.md, patient-experience-and-advocacy.md
Gantagad T, et al. Cultural and Contextual Barriers to Sustained Home Blood Pressure Monitoring Practices Among Indigenous People in Northern Thailand: A Qualitative Study. Int J Community Based Nurs Midwifery. 2025;13:274-285. PMID 41189998 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Oyando R, et al. Access to hypertension services and health-seeking experiences in rural Coastal Kenya: A qualitative study. PLOS Glob Public Health. 2025;5:e0004324. PMID 41270024 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Perry M, et al. A scoping review of qualitative studies examining the factors influencing hypertension treatment adherence in East Africa. J Biosoc Sci. 2025;57:649-670. PMID 41414744 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Hill M, et al. Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia. BMC Cardiovasc Disord. 2026;26. PMID 42321603 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
Sun G, et al. Long-Term Effectiveness of Intensive Blood Pressure Management Led by Nonphysician Community Healthcare Providers on Cardiovascular Events: 7-Year Follow-Up of a Cluster Randomized Trial. Circulation. 2026;:10.1161/CIRCULATIONAHA.126.082511. PMID 42666029 — tags: [lifestyle-and-population-prevention, implementation, intensive-target] — cited by: lifestyle-and-population-prevention.md
Liao LP, et al. Mediterranean versus Dietary Approaches to Stop Hypertension (DASH) Diets and Heart Failure Risk: A UK Biobank Study. Clin Nutr ESPEN. 2026;:105067. PMID 42660494 — tags: [lifestyle-and-population-prevention, diet] — cited by: catalogued only (observational; DASH aHR 0.89 for incident HF after adjustment for hypertension, obesity and diabetes)
Nesterovich Grushina D, et al. Gender-related determinants of hypertension self-care behaviours in primary care: Perspectives of patients and healthcare professionals. Aten Primaria. 2026;58(11):103589. PMID 42667829 — tags: [patient-voice, qualitative, adherence] — cited by: patient-voice/sources.md
Debalucos EJD, et al. Self-care Practices of Hypertensive Adult Female Patients in the City of Marikina amidst the COVID-19 Lockdown: A Phenomenological Inquiry. Acta Med Philipp. 2026;60(14):36-49. PMID 42668679 — tags: [patient-voice, qualitative, access] — cited by: patient-voice/sources.md

Guidelines and clinical trials¶

Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-e115. PMID 29133356 — tags: [superseded-guideline, United-States] — cited by: literature/guidelines/REGISTRY.md
Owolabi M, et al. Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review. Hypertension. 2016;68:1328-1337. PMID 27698059 — tags: [guidelines] — cited by: guidelines.md
Boffa RJ, et al. Hypertension in adults: summary of updated NICE guidance. BMJ. 2019;367:l5310. PMID 31636059 — tags: [guidelines] — cited by: guidelines.md
Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334-1357. PMID 32370572 — tags: [guidelines] — cited by: guidelines.md
Jones ES, et al. PASCAR commentary on the International Society of Hypertension global guidelines 2020: relevance to sub-Saharan Africa. Cardiovasc J Afr. 2020;31:325-329. PMID 33404583 — tags: [guidelines] — cited by: guidelines.md
Zheng X, et al. Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial. Hypertens Res. 2023;46:1493-1503. PMID 36854725 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874-2071. PMID 37345492 — tags: [guidelines] — cited by: guidelines.md
Singh S, et al. Renal denervation in hypertension: An updated meta-analysis of the randomized controlled trials. Catheter Cardiovasc Interv. 2023;102:663-671. PMID 37545184 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
Writing Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83:109-279. PMID 38043043 — tags: [guidelines] — cited by: guidelines.md
Ogoyama Y, et al. Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res. 2024;47:2745-2759. PMID 38831091 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
Kreutz R, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15. PMID 38914505 — tags: [guidelines] — cited by: guidelines.md
Cohen JB. What Is New in the ESC Hypertension Guideline? Hypertension. 2025;82:11-13. PMID 39284002 — tags: [guidelines] — cited by: guidelines.md
Dantas CR, et al. Systematic Review and Meta-Analysis of Second-Generation Sham-Controlled Randomized Trials of Renal Denervation Therapy for Patients with Hypertension. High Blood Press Cardiovasc Prev. 2024;31:669-676. PMID 39395908 — tags: [clinical-trials-landscape] — cited by: clinical-trials-landscape.md
Ditlhabolo KI, et al. Hypertension guideline implementation and blood pressure control in Matlosana, South Africa. S Afr Fam Pract (2004). 2024;66:e1-e10. PMID 39494661 — tags: [guidelines] — cited by: guidelines.md
McCarthy CP, et al. What Is New and Different in the 2024 European Society of Cardiology Guidelines for the Management of Elevated Blood Pressure and Hypertension? Hypertension. 2025;82:432-444. PMID 39970254 — tags: [guidelines] — cited by: guidelines.md
Burlacu A, et al. Key Updates to the 2024 ESC Hypertension Guidelines and Future Perspectives. Medicina (Kaunas). 2025;61. PMID 40005310 — tags: [guidelines] — cited by: guidelines.md
Goupil R, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197:E549-E564. PMID 40419299 — tags: [guidelines] — cited by: guidelines.md
Goupil R, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. Can Fam Physician. 2025;71:467-482. PMID 40527605 — tags: [guidelines] — cited by: guidelines.md
Brown C, et al. Updates in the 2025 AHA/ACC Hypertension Guideline. Curr Hypertens Rep. 2026;28. PMID 41843050 — tags: [guidelines] — cited by: guidelines.md
Køber L, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;:ehag100. PMID 42661420 — tags: [guidelines, heart-failure] — cited by: guidelines.md, guidelines/REGISTRY.md — note: record resolved live 2026-08-31; document text not read, no recommendation asserted
Damman K, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026;:ehag098. PMID 42661426 — tags: [guidelines, chronic-kidney-disease] — cited by: guidelines.md, guidelines/REGISTRY.md — note: record resolved live 2026-08-31; document text not read, no recommendation asserted
Yee-Moon Wang A, et al. Asia-Pacific Summit on Implementation of Clinical Practice Guidelines on Diabetes and Blood Pressure Management in Chronic Kidney Disease: A KDIGO Summit Report. Kidney Int. 2026;:S0085-2538(26)00715-5. PMID 42660227 — tags: [guidelines, implementation, chronic-kidney-disease] — cited by: guidelines/REGISTRY.md